title: Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?
authors.affiliation: Medical Oncology Department, Santa Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
authors.affiliation: Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Nima
authors.initials: N
authors.lastname: Sharifi
mesh_terms: D000069501:Abiraterone Acetate; D000736:Androstenes / Q000494:pharmacology*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant; D013375:Substance Withdrawal Syndrome
chemical_list: D000736:Androstenes; D000069501:Abiraterone Acetate; C089740:abiraterone